Suppr超能文献

一项随机试验的 24 个月结果,比较氰基丙烯酸酯封闭与射频消融治疗功能不全大隐静脉的效果。

Twenty-four month results from a randomized trial of cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins.

机构信息

Lake Washington Vascular, Bellevue, Wash.

Morrison Vein Institute, Scottsdale, Ariz.

出版信息

J Vasc Surg Venous Lymphat Disord. 2018 Sep;6(5):606-613. doi: 10.1016/j.jvsv.2018.04.009. Epub 2018 Jun 15.

Abstract

OBJECTIVE

We previously reported 3-month and 12-month occlusion rates after treatment of clinically symptomatic saphenous vein reflux with either cyanoacrylate closure (CAC) using the VenaSeal Closure System (Medtronic, Dublin, Ireland) or radiofrequency ablation (RFA) in a randomized, multicenter, clinical trial, VenaSeal Sapheon Closure System vs Radiofrequency Ablation for Incompetent Great Saphenous Veins (VeClose). Herein we report the 24-month follow-up results of the VeClose trial.

METHODS

There were 222 patients with symptomatic great saphenous vein (GSV) incompetence who were randomly assigned to receive either CAC (n = 108) or RFA (n = 114). Patients were not allowed to receive adjunctive treatment of tributary varicosities until after the 3-month visit. Duplex ultrasound of the target vein was performed at day 3 and months 1, 3, 6, 12, and 24 after treatment, and closure was assessed by ultrasound by the treating physician. Overall 24-month success rates were compared; in addition, time to first reopening of the target vein was evaluated using survival analysis. End points such as Venous Clinical Severity Score, EuroQoL-5 Dimension, and Aberdeen Varicose Vein Questionnaire were evaluated.

RESULTS

Of 222 randomized patients, 171 completed the 24-month follow-up, which included 87 from the CAC group and 84 from the RFA group. The 24-month complete closure rate was 95.3% in the CAC group and 94.0% in the RFA group, demonstrating continued noninferiority of CAC compared with RFA (P = .0034). Symptoms and quality of life improved similarly in both groups. No clinically significant device- or procedure-related late adverse events occurred.

CONCLUSIONS

Both CAC and RFA were effective in closure of the target GSV, resulting in similar and significant improvements in the patient's quality of life through 24 months. These results suggest that CAC of the GSV is safe and durable out to 2 years.

摘要

目的

我们之前报道了一项随机、多中心临床试验的 3 个月和 12 个月的静脉症状性隐静脉反流治疗后的闭塞率,使用氰基丙烯酸酯闭合(CAC)(使用 VenaSeal 闭合系统[Medtronic,都柏林,爱尔兰])或射频消融(RFA)。在此,我们报告了 VeClose 试验的 24 个月随访结果。

方法

共有 222 例有症状的大隐静脉(GSV)功能不全患者被随机分配接受 CAC(n=108)或 RFA(n=114)治疗。直到 3 个月就诊后,才允许患者对属支静脉曲张进行辅助治疗。治疗后第 3 天和第 1、3、6、12 和 24 个月对目标静脉进行超声检查,由治疗医生通过超声评估闭合情况。比较总体 24 个月的成功率;此外,使用生存分析评估目标静脉首次再通的时间。评估终点包括静脉临床严重程度评分、欧洲五维健康量表和阿伯丁静脉曲张问卷。

结果

在 222 例随机患者中,171 例完成了 24 个月的随访,其中 CAC 组 87 例,RFA 组 84 例。CAC 组的 24 个月完全闭塞率为 95.3%,RFA 组为 94.0%,表明 CAC 与 RFA 相比仍具有非劣效性(P=0.0034)。两组患者的症状和生活质量均有类似的改善。两组均未发生与器械或手术相关的迟发性不良事件。

结论

CAC 和 RFA 均能有效闭合目标 GSV,通过 24 个月,患者的生活质量均有显著改善。这些结果表明,在 2 年内,CAC 治疗 GSV 是安全且持久的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验